You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethyldopa
Accession NumberDB00968  (APRD01106)
TypeSmall Molecule
GroupsApproved
DescriptionAn alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. [PubChem]
Structure
Thumb
Synonyms
(S)-(-)-alpha-Methyldopa
3-Hydroxy-alpha-methyl-L-tyrosine
Alpha medopa
alpha-Methyl dopa
alpha-methyl-L-dopa
Alphamethyldopa
AMD
Anhydrous methyldopa
L-alpha-Methyldopa
L-Methyl Dopa
Methyl dopa
Methyldopa anhydrous
α-Methyl dopa
α-methyl-L-dopa
External Identifiers
  • Bayer 1440L
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aldomet Ester HCl InjLiquid250 mgIntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1963-12-312002-07-29Canada
Aldomet Tab 125mgTablet125 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1971-12-311998-08-14Canada
Aldomet Tab 250mgTablet250 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1963-12-312004-11-12Canada
Aldomet Tab 500mgTablet500 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1971-12-311998-08-14Canada
Dopamet Tab 125mgTablet125 mgOralIcn Canada Ltd.1976-12-312005-04-26Canada
Dopamet Tab 250mgTablet250 mgOralIcn Canada Ltd.1972-12-312005-04-26Canada
Dopamet Tab 500mgTablet500 mgOralIcn Canada Ltd.1976-12-312005-04-26Canada
Medimet 250tabTablet250 mgOralMedic Laboratory LtÉe1976-12-311996-09-09Canada
MethyldopaTablet125 mgOralAa Pharma Inc1980-04-02Not applicableCanada
MethyldopaTablet250 mgOralAa Pharma Inc1976-12-31Not applicableCanada
MethyldopaTablet500 mgOralAa Pharma Inc1978-12-31Not applicableCanada
Methyldopa 125 Tab 125mgTablet125 mgOralPro Doc Limitee1978-12-312009-07-23Canada
Methyldopa 250 TabTablet250 mgOralPro Doc Limitee1978-12-312009-07-23Canada
Methyldopa 500 Tab 500mgTablet500 mgOralPro Doc Limitee1978-12-312009-07-23Canada
Methyldopa Tablets 125mgTablet125 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Methyldopa Tablets 250mgTablet250 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Methyldopa Tablets 500mgTablet500 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Novo-medopa Tab 125mgTablet125 mgOralNovopharm Limited1975-12-312015-10-26Canada
Novo-medopa Tab 250mgTablet250 mgOralNovopharm Limited1975-12-312015-10-26Canada
Novo-medopa Tab 500mgTablet500 mgOralNovopharm Limited1975-12-312015-10-26Canada
Nu-medopa Tab 125mgTablet125 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-medopa Tab 250mgTablet250 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-medopa Tab 500mgTablet500 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethyldopaTablet, film coated250 mg/1OralRebel Distributors Corp1984-02-20Not applicableUs
MethyldopaTablet, film coated250 mg/1OralCarilion Materials Management2012-07-24Not applicableUs
MethyldopaTablet, film coated250 mg/1OralTeva Pharmaceuticals USA Inc2009-02-23Not applicableUs
MethyldopaTablet, film coated500 mg/1OralA S Medication Solutions Llc2009-04-28Not applicableUs
MethyldopaTablet, film coated500 mg/1OralRebel Distributors Corp1984-02-20Not applicableUs
MethyldopaTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2009-04-28Not applicableUs
MethyldopaTablet250 mg/1OralMylan Institutional Inc.1998-09-01Not applicableUs
MethyldopaTablet, film coated250 mg/1OralPhysicians Total Care, Inc.1995-08-29Not applicableUs
MethyldopaTablet, film coated250 mg/1OralAccord Healthcare Inc.2012-06-27Not applicableUs
MethyldopaTablet, film coated250 mg/1OralRebel Distributors Corp2009-02-23Not applicableUs
MethyldopaTablet500 mg/1OralMylan Pharmaceuticals Inc.1985-04-18Not applicableUs
MethyldopaTablet500 mg/1OralMylan Institutional Inc.1998-09-01Not applicableUs
MethyldopaTablet, film coated500 mg/1OralPhysicians Total Care, Inc.1996-07-26Not applicableUs
MethyldopaTablet, film coated500 mg/1OralAccord Healthcare Inc.2012-06-27Not applicableUs
MethyldopaTablet250 mg/1OralREMEDYREPACK INC.2012-09-25Not applicableUs
MethyldopaTablet250 mg/1OralMylan Pharmaceuticals Inc.1985-04-18Not applicableUs
MethyldopaTablet250 mg/1OralCardinal Health2011-08-23Not applicableUs
Methyldopate HydrochlorideInjection, solution50 mg/mLIntravenousAmerican Regent, Inc.1995-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AldometNot Available
AldometilNot Available
AldominNot Available
DopametNot Available
HypolagNot Available
MedometNot Available
MedoprenNot Available
NovomedopaNot Available
Nu-MedopaNot Available
Brand mixtures
NameLabellerIngredients
Aldoril 15 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Aldoril 25 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Apo Methazide 15Apotex Inc
Apo Methazide 25Apotex Inc
Methyldopa and HydrochlorothiazideMylan Pharmaceuticals Inc.
Novo-doparil 15 TabNovopharm Limited
Novo-doparil 25 TabNovopharm Limited
PMS-dopazide 15 TabPharmascience Inc
PMS-dopazide-25 TabPharmascience Inc
Supres 150 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Supres 250 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Methyldopa hydrochloride
ThumbNot applicableDBSALT001139
Methyldopa sesquihydrate
41372-08-1
Thumb
  • InChI Key: YKFCISHFRZHKHY-NGQGLHOPSA-N
  • Monoisotopic Mass: 476.200609858
  • Average Mass: 476.479
DBSALT000988
Categories
UNIIM4R0H12F6M
CAS number555-30-6
WeightAverage: 211.2145
Monoisotopic: 211.084457909
Chemical FormulaC10H13NO4
InChI KeyCJCSPKMFHVPWAR-UEQNJFAPNA-N
InChI
InChI=1/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/s2
IUPAC Name
(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
SMILES
C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
Pharmacology
IndicationFor use in the treatment of hypertension.
Structured Indications
PharmacodynamicsMethyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.
Mechanism of actionAlthough the mechanism of action has yet to be conclusively demonstrated, the resultant hypotensive effect is most likely due to the drug's action on the CNS. Methyldopa is converted into the metabolite, alpha-methylnorepinephrine, in the CNS, where it stimulates the central inhibitory alpha-adrenergic receptors, leading to a reduction in sympathetic tone, total peripheral resistance, and blood pressure. Reduction in plasma renin activity, as well as the inhibition of both central and peripheral norepinephrine and serotonine production may also contribute to the drug's antihypertensive effect, although this is not a major mechanism of action. This is done through the inhibition of the decarboxylation of dihydroxyphenylalanine (dopa)—the precursor of norepinephrine—and of 5-hydroxytryptophan (5-HTP)—the precursor of serotonin—in the CNS and in most peripheral tissues.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2A adrenergic receptorProteinyesNot AvailableHumanP08913 details
Aromatic-L-amino-acid decarboxylaseProteinunknownNot AvailableHumanP20711 details
Related Articles
AbsorptionAbsorption from the gastrointestinal tract is variable but averages approximately 50%.
Volume of distributionNot Available
Protein bindingLow (less than 20%).
Metabolism

Hepatic, extensively metabolized. The known urinary metabolites are: a-methyldopa mono-0-sulfate; 3-0-methyl-a-methyldopa; 3,4-dihydroxyphenylacetone; a-methyldopamine; 3-0-methyl-a-methyldopamine and their conjugates.

SubstrateEnzymesProduct
Methyldopa
Not Available
3-O-methyl-a-methyldopaDetails
Methyldopa
Not Available
3-O-methyl-a-methyldopamineDetails
Methyldopa
Not Available
a-methyldopa mono-0-sulfateDetails
Methyldopa
Not Available
a-methyldopamineDetails
Route of eliminationMethyldopa is extensively metabolized. The known urinary metabolites are: α-methyldopa mono-O-sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates. Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-O-sulfate conjugate. Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.
Half lifeThe plasma half-life of methyldopa is 105 minutes.
Clearance
  • Renal cl=130 mL/min [healthy]
ToxicityThe oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Methyldopa.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Methyldopa.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Methyldopa is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Methyldopa.Approved, Withdrawn
AmbrisentanMethyldopa may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMethyldopa may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Methyldopa.Approved
AmiodaroneMethyldopa may increase the bradycardic activities of Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Methyldopa.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Methyldopa.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Methyldopa is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Methyldopa is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Methyldopa.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Methyldopa.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Methyldopa.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Methyldopa is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Methyldopa.Experimental
BarbitalBarbital may increase the hypotensive activities of Methyldopa.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Methyldopa.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methyldopa.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Methyldopa.Withdrawn
Benzylpenicilloyl PolylysineMethyldopa may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilMethyldopa may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantMethyldopa may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyldopa.Approved
BethanidineBethanidine may increase the hypotensive activities of Methyldopa.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Methyldopa.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methyldopa.Approved
BortezomibThe risk or severity of adverse effects can be increased when Methyldopa is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Methyldopa.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Methyldopa.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methyldopa.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Methyldopa.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Methyldopa.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Methyldopa.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Methyldopa.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Bupivacaine.Approved, Investigational
BupranololMethyldopa may increase the hypotensive activities of Bupranolol.Approved
CabergolineCabergoline may increase the hypertensive activities of Methyldopa.Approved
CalfactantMethyldopa may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Methyldopa.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Methyldopa.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Methyldopa is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Carbetocin.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Methyldopa.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Methyldopa.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Methyldopa is combined with Carvedilol.Approved, Investigational
CeliprololMethyldopa may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibMethyldopa may increase the bradycardic activities of Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Methyldopa.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Methyldopa.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Methyldopa is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methyldopa.Approved
ClozapineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Methyldopa is combined with Conivaptan.Approved, Investigational
CrizotinibMethyldopa may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Methyldopa.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Methyldopa.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.Approved
DebrisoquinMethyldopa may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineMethyldopa may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Methyldopa is combined with Desflurane.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Methyldopa.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methyldopa.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Methyldopa.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Diclofenamide.Approved
DigoxinDigoxin may increase the bradycardic activities of Methyldopa.Approved
DihydralazineMethyldopa may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Methyldopa.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Methyldopa.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dipyridamole.Approved
DonepezilDonepezil may increase the bradycardic activities of Methyldopa.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Methyldopa.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Methyldopa.Approved
DronedaroneMethyldopa may increase the bradycardic activities of Dronedarone.Approved
DuloxetineMethyldopa may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineMethyldopa may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Methyldopa.Approved, Vet Approved
EnalaprilatMethyldopa may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe metabolism of Methyldopa can be decreased when combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Methyldopa.Approved
EpoprostenolMethyldopa may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Methyldopa.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Methyldopa.Approved
ErgonovineErgonovine may increase the hypertensive activities of Methyldopa.Approved
ErgotamineErgotamine may increase the hypertensive activities of Methyldopa.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyldopa.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methyldopa.Approved
FelodipineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Felodipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Methyldopa.Approved
Ferric CarboxymaltoseThe serum concentration of Methyldopa can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Methyldopa can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Methyldopa can be decreased when it is combined with Ferric pyrophosphate.Approved
FimasartanThe risk or severity of adverse effects can be increased when Methyldopa is combined with Fimasartan.Approved
FingolimodMethyldopa may increase the bradycardic activities of Fingolimod.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methyldopa.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methyldopa.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Methyldopa.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Methyldopa.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Methyldopa.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Methyldopa.Approved
GuanethidineMethyldopa may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Methyldopa is combined with Halothane.Approved, Vet Approved
HexamethoniumMethyldopa may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Methyldopa.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Methyldopa.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Methyldopa.Approved
HydralazineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Methyldopa.Approved
IloprostIloprost may increase the hypotensive activities of Methyldopa.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Methyldopa is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Methyldopa.Approved
IndenololMethyldopa may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminMethyldopa may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Methyldopa.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Methyldopa.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methyldopa.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Methyldopa is combined with Irbesartan.Approved, Investigational
IronThe serum concentration of Methyldopa can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Methyldopa can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Methyldopa can be decreased when it is combined with Iron saccharate.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyldopa.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Methyldopa is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Methyldopa.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Methyldopa is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Methyldopa.Approved
IvabradineMethyldopa may increase the bradycardic activities of Ivabradine.Approved
KetanserinMethyldopa may increase the hypotensive activities of Ketanserin.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Methyldopa.Approved
LacidipineMethyldopa may increase the hypotensive activities of Lacidipine.Approved
LacosamideMethyldopa may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideMethyldopa may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Methyldopa.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Methyldopa.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Levobupivacaine.Approved
LevodopaMethyldopa may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Methyldopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Methyldopa is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Methyldopa.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.Approved
LofexidineMethyldopa may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Methyldopa.Approved
LucinactantMethyldopa may increase the bradycardic activities of Lucinactant.Approved
MacitentanMethyldopa may increase the hypotensive activities of Macitentan.Approved
ManidipineMethyldopa may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Methyldopa.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Methyldopa.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methyldopa.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Methyldopa.Approved
MethohexitalMethohexital may increase the hypotensive activities of Methyldopa.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Methyldopa.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Methyldopa.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Methyldopa.Approved
MetipranololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Methyldopa.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Methyldopa.Approved, Investigational
MetyrosineMethyldopa may increase the hypotensive activities of Metyrosine.Approved
MibefradilMethyldopa may increase the hypotensive activities of Mibefradil.Withdrawn
MilnacipranMilnacipran may increase the tachycardic activities of Methyldopa.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Methyldopa.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Methyldopa.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methyldopa.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Methyldopa.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Methyldopa.Approved
MorphineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Morphine.Approved, Investigational
MoxonidineMethyldopa may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nadolol.Approved
NaftopidilMethyldopa may increase the hypotensive activities of Naftopidil.Investigational
NebivololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nesiritide.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Methyldopa.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Methyldopa.Approved
NicorandilNicorandil may increase the hypotensive activities of Methyldopa.Approved
NifedipineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nifedipine.Approved
NiguldipineMethyldopa may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMethyldopa may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Methyldopa.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Methyldopa.Approved
NitrendipineMethyldopa may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Methyldopa.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Methyldopa.Approved
ObinutuzumabMethyldopa may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Methyldopa.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Methyldopa.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Methyldopa.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Methyldopa.Investigational
OxprenololMethyldopa may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Methyldopa is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Papaverine.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Methyldopa.Approved
PasireotideMethyldopa may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Methyldopa is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Methyldopa.Approved, Vet Approved
PentoliniumMethyldopa may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Methyldopa.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Methyldopa.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methyldopa.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Methyldopa.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Methyldopa.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Methyldopa.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Methyldopa.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Methyldopa.Approved
PinacidilMethyldopa may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Methyldopa.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methyldopa is combined with Pipamperone.Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methyldopa.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Methyldopa.Withdrawn
PolythiazideMethyldopa may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaMethyldopa may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Methyldopa is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Methyldopa.Approved
PrimidonePrimidone may increase the hypotensive activities of Methyldopa.Approved, Vet Approved
PropafenoneMethyldopa may increase the bradycardic activities of Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Methyldopa is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Methyldopa.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Methyldopa.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Methyldopa.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Methyldopa.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methyldopa.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Methyldopa is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Methyldopa.Approved
RescinnamineMethyldopa may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyldopa.Approved
RilmenidineMethyldopa may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Methyldopa is combined with Riociguat.Approved
RisperidoneMethyldopa may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMethyldopa may increase the hypotensive activities of Rituximab.Approved
RivastigmineMethyldopa may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Methyldopa is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Methyldopa.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Methyldopa is combined with Sacubitril.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Methyldopa.Withdrawn
SaprisartanMethyldopa may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Methyldopa.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methyldopa.Approved, Investigational, Vet Approved
SelexipagMethyldopa may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Methyldopa is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Methyldopa.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Methyldopa.Approved
SitaxentanMethyldopa may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Methyldopa is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Methyldopa.Approved
SpiraprilMethyldopa may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Methyldopa.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Methyldopa is combined with Streptokinase.Approved
SufentanilSufentanil may increase the bradycardic activities of Methyldopa.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Methyldopa.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Methyldopa.Approved, Investigational
TemocaprilMethyldopa may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Terazosin.Approved
TerlipressinMethyldopa may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe metabolism of Methyldopa can be decreased when combined with Testosterone Propionate.Approved, Vet Approved
ThalidomideThe risk or severity of adverse effects can be increased when Methyldopa is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Methyldopa.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Methyldopa.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Methyldopa is combined with Thioridazine.Approved
TiboloneMethyldopa may increase the hypotensive activities of Tibolone.Approved
TicrynafenMethyldopa may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Methyldopa.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methyldopa.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Methyldopa.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Methyldopa.Approved, Vet Approved
TolcaponeThe metabolism of Methyldopa can be decreased when combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Methyldopa.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyldopa.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Methyldopa.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methyldopa.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyldopa.Approved
TravoprostTravoprost may increase the hypotensive activities of Methyldopa.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Methyldopa.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Methyldopa is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa.Approved
TrichlormethiazideMethyldopa may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinMethyldopa may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanMethyldopa may increase the hypotensive activities of Trimethaphan.Approved
UdenafilUdenafil may increase the antihypertensive activities of Methyldopa.Approved, Investigational
UnoprostoneMethyldopa may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyldopa.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Methyldopa.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Methyldopa.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.Approved
VinpocetineMethyldopa may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineMethyldopa may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Methyldopa.Approved, Vet Approved
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • May take Vitamin D.
  • No iron, zinc or fluoride within 2 hours of taking this medication.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US2868818
General References
  1. Mah GT, Tejani AM, Musini VM: Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003893. doi: 10.1002/14651858.CD003893.pub3. [PubMed:19821316 ]
  2. McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. 2009 Feb 15;66(4):337-44. doi: 10.2146/ajhp080104. [PubMed:19202042 ]
  3. Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. [PubMed:17485976 ]
  4. van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12. [PubMed:1363322 ]
  5. Rosenthal T, Oparil S: The effect of antihypertensive drugs on the fetus. J Hum Hypertens. 2002 May;16(5):293-8. [PubMed:12082488 ]
  6. van Zwieten PA, Timmermans PB: Pharmacology and characterization of central alpha-adrenoceptors involved in the effect of centrally acting antihypertensive drugs. Chest. 1983 Feb;83(2 Suppl):340-3. [PubMed:6295709 ]
  7. van Zwieten PA: Pharmacology of centrally acting hypotensive drugs. Br J Clin Pharmacol. 1980;10 Suppl 1:13S-20S. [PubMed:6104975 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 24:08.16
PDB EntriesNot Available
FDA labelDownload (155 KB)
MSDSDownload (53.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9374
Blood Brain Barrier-0.9276
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6066
P-glycoprotein inhibitor INon-inhibitor0.9852
P-glycoprotein inhibitor IINon-inhibitor0.9895
Renal organic cation transporterNon-inhibitor0.9357
CYP450 2C9 substrateNon-substrate0.7757
CYP450 2D6 substrateNon-substrate0.8
CYP450 3A4 substrateNon-substrate0.6053
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9369
CYP450 2D6 inhibitorNon-inhibitor0.9491
CYP450 2C19 inhibitorNon-inhibitor0.9233
CYP450 3A4 inhibitorNon-inhibitor0.864
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9551
Ames testNon AMES toxic0.8185
CarcinogenicityNon-carcinogens0.8997
BiodegradationNot ready biodegradable0.8077
Rat acute toxicity1.6281 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.9629
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidIntravenous250 mg
TabletOral125 mg
TabletOral250 mg
TabletOral250 mg/1
TabletOral500 mg/1
TabletOral500 mg
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
TabletOral
Injection, solutionIntravenous50 mg/mL
Prices
Unit descriptionCostUnit
Aldoclor 250-250 mg tablet0.67USD tablet
Methyldopa 500 mg tablet0.67USD tablet
Methyldopa 250 mg tablet0.39USD tablet
Apo-Methyldopa 500 mg Tablet0.27USD tablet
Methyldopate 250 mg/5 ml vial0.24USD ml
Apo-Methyldopa 250 mg Tablet0.15USD tablet
Apo-Methyldopa 125 mg Tablet0.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point300 dec °CPhysProp
water solubility1E+004 mg/L (at 25 °C)MERCK INDEX (1996)
logP-1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.26 mg/mLALOGPS
logP-2ALOGPS
logP-1.4ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)1.73ChemAxon
pKa (Strongest Basic)9.85ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area103.78 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity53.79 m3·mol-1ChemAxon
Polarizability20.73 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentCatecholamines and derivatives
Alternative Parents
Substituents
  • 3-phenylpropanoic-acid
  • Catecholamine
  • L-alpha-amino acid
  • D-alpha-amino acid
  • Amphetamine or derivatives
  • Alpha-amino acid or derivatives
  • Alpha-amino acid
  • Phenylpropane
  • Aralkylamine
  • Amino fatty acid
  • Fatty acyl
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. [PubMed:17485976 ]
  4. Kawasaki H: [Centrally acting sympathetic inhibitors for therapy of patients with hypertension]. Nihon Rinsho. 1997 Aug;55(8):2081-5. [PubMed:9284427 ]
  5. Head GA: Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann N Y Acad Sci. 1999 Jun 21;881:279-86. [PubMed:10415926 ]
  6. van Zwieten PA: New central mediators as targets of centrally acting antihypertensive drugs. Clin Exp Hypertens. 1996 Apr-May;18(3-4):291-303. [PubMed:8743022 ]
  7. van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12. [PubMed:1363322 ]
  8. Velliquette RA, Ernsberger P: Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther. 2003 Dec;307(3):1104-11. Epub 2003 Oct 13. [PubMed:14557373 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Pyridoxal phosphate binding
Specific Function:
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
Gene Name:
DDC
Uniprot ID:
P20711
Molecular Weight:
53925.815 Da
References
  1. SOURKES TL: Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine. Arch Biochem Biophys. 1954 Aug;51(2):444-56. [PubMed:13189588 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Alazizi A, Liu MY, Williams FE, Kurogi K, Sakakibara Y, Suiko M, Liu MC: Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23. doi: 10.1016/j.aquatox.2010.12.016. Epub 2010 Dec 29. [PubMed:21371608 ]
  2. Ameyaw MM, Syvanen AC, Ulmanen I, Ofori-Adjei D, McLeod HL: Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Hum Mutat. 2000 Nov;16(5):445-6. [PubMed:11058906 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50. [PubMed:10052994 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23